GLP-1 RECEPTOR AGONISTS IN CHRONIC KIDNEY DISEASE: NEPHROPROTECTION BEYOND GLYCEMIC CONTROL - A REVIEW OF CURRENT LITERATURE
Authors:
- Anna MamachAMAnna Mamach
- Aleksandra WoźniakAWAleksandra Woźniak
- Patrycja SobantkaPSPatrycja Sobantka
- Szymon MokrzeckiSMSzymon Mokrzecki
- Matylda KrólMKMatylda Król
- Katarzyna AleksandrowiczKAKatarzyna Aleksandrowicz
- Zofia GrodzkaZGZofia Grodzka
- Mateusz MeszkaMMMateusz Meszka
- Ewa BełcEBEwa Bełc
- Karolina BrzezińskaKBKarolina Brzezińska
Open Access
- 30 June 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Abstract
Background: Chronic Kidney Disease (CKD) is currently one of the major global health burdens and the number of people affected by this disease is still rising. CKD is strongly associated with type 2 diabetes mellitus (T2DM), obesity and cardiovascular diseases. Despite the fact that glucagon-like-peptide-1 receptor agonists were primarily developed as glucose-lowering agents, accumulating evidence suggests that their benefits extend beyond glycemic control and include significant renoprotective effects. Aim: This review synthesises current evidence on the nephroprotective effects of GLP-1 receptor agonists in patients with CKD with emphasis on clinical trials outcomes and future therapeutic perspectives. Materials and Methods: A narrative review of current literature was conducted in PubMed, Google Scholar, and Scopus. Relevant randomized controlled trials, meta-analyses, and recent review articles published between 2019 and 2026 were analyzed. Results: GLP-1 receptor agonists expend nephroprotective effects through multiple pathways, including reduction of systemic inflammation, oxidative stress, endothelial dysfunction, albuminuria and intraglomerular hypertension. Additional benefits arise from weight reduction, blood pressure lowering and cardiovascular protection. Clinical trials such as LEADER, SUSTAIN-6, REWIND, and particularly the FLOW trial demonstrated significant reductions in renal composite outcomes and slower decline in estimated glomerular filtration rate (eGFR). The FLOW trial provided the first dedicated evidence that semaglutide significantly reduces the risk of kidney disease progression and cardiovascular death in patients with T2DM and CKD. Conclusions: Current evidence suggests that GLP-1 receptor agonists represent an emerging nephroprotective therapy with benefits extending far beyond glycemic control. Their pleiotropic effects may position GLP-1 RAs as an important component of future cardio–renal–metabolic management strategies in CKD patients. Further studies are needed to clarify their role in non-diabetic CKD and advanced kidney disease.Keywords
This publication has 39 references indexed in Scilit:
- Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialJACC, 2024
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-artMolecular Metabolism, 2021
- Preliminary study on the mechanism of long noncoding RNA SENCR regulating the proliferation and migration of vascular smooth muscle cellsJournal of Cellular Physiology, 2020
- Glucagon-like peptide 1 (GLP-1)Molecular Metabolism, 2019
- A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseasesKidney International, 2019
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1Cell Metabolism, 2018
- Obesity and kidney disease: hidden consequences of the epidemicKidney International, 2017
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone ActionCell Metabolism, 2013
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetesDiabetologia, 2011